Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach. Issue 2 (June 2022)

• Record Type: Journal Article
• Authors: Rampotas, Alexandros; Hargreaves, Rupen; McLornan, Donal P.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 35:Issue 2(2022)
• Publication Date: 2022-06
• Subjects: Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2022.101378
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Pre-Fibrotic Myelofibrosis is a frequently under-recognised entity that has distinct features separate to those of both Essential Thrombocythaemia and overt Primary Myelofibrosis. Misdiagnosis is relatively common due to subtle differences in bone marrow trephine morphology and multidisciplinary approaches are required. The clinical phenotype and disease course is heterogeneous and hence management approaches tend to vary widely. Although patients may initially be asymptomatic, disease-related complications can include troublesome symptom burdens, increased incidence of both arterial and venous thromboses, haemorrhage, anaemia and an inherent risk of disease evolution to either overt myelofibrosis or blastic phase disease. Specific prognostic tools with high discriminatory power are lacking. Within this review we use case-based approaches to review the current literature, highlight challenges in both diagnostics and disease management and suggest contemporary approaches to improve patient outcomes.